Eylea, Regeneron Pharmaceuticals

Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
What’s new for diabetes management and prevention
What’s new for diabetes management and preventionFrom new ways of predicting who will and won’t develop diabetes, to new diabetes meds, to new evidence regarding which anti-vascular endothelial growth factor (VEGF) might be better for your specific patient, the last year has given us better tools for helping our patients with diabetes.
Anti-VEGF agent therapy rivals laser for macular edema in BRVOPatients treated with aflibercept intravitreal injections for macular edema associated with branch retinal vein occlusion had a significantly greater decrease in central retinal thickness and significantly greater improvement in vision compared with laser at the end of the 52-week VIBRANT trial.
Eylea far better for DME patients, NIH study reports
Eylea far better for DME patients, NIH study reportsAflibercept is reportedly superior to ranibizumab and bevacizumab when treating some patients with diabetic macular edema (DME), according to a National Institutes of Health (NIH)-sponsored clinical trial.
AMD treatment market to exceed $10 billion by 2023According to a report from GlobalData, the age-related macular degeneration treatment market in the U.S., UK, Germany, France, Spain, Italy, and Japan will double in value from $5.1 billion in 2013 to $10.1 billion in 2023.
FDA grants priority review to aflibercept for diabetic retinopathy in patients with DMEThe FDA has accepted for priority review Regeneron Pharmaceuticals’ supplemental biologics license application for aflibercept (Eylea) injection, a treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
Health Canada approves Eyelea for DME treatmentHealth Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).
FDA drug approvals December 2014
Drugs for AMD and DME still in center courtMuch of the developments in pharmacologic therapy for retina disease revolved around age-related macular degeneration and diabetic macular edema in 2014.
Aflibercept performance consistent in DME regardless of prior anti-VEGF therapyOutcomes from a study of intravitreal aflibercept were evaluated for patients with and without prior anti-vascular endothelial growth factor therapy for diabetic macular edema.